EpicGenetics, Universities Seek to Expand Fibromyalgia Genetic Markers Program, FM/a Test

EpicGenetics, Universities Seek to Expand Fibromyalgia Genetic Markers Program, FM/a Test
EpicGenetics is collaborating with the University of California, Los Angeles (UCLA) and the University of Illinois College of Medicine Chicago (UIC) to gather genetic information from fibromyalgia patients to improve the diagnosis capacity of its FM/a Test. This goal of this project is to detect fibromyalgia disease-specific genetic markers. Based on the quantification of several blood biomarkers that have been associated with fibromyalgia, the FM/a Test can accurately and objectively diagnose this medical condition. It is an FDA-compliant blood test that has been clinically validated, presenting a 93% sensitivity to diagnose fibromyalgia. “Since becoming available in 2012, the FM/a Test has successfully and objectively diagnosed patients with fibromyalgia in the U.S. and multiple other countries, thereby providing these patients with a definitive diagnosis and certainty about a medical condition that has often been misunderstood and erroneously denied as a legitimate medical disorder,” said Bruce Gillis, CEO of EpicGenetics, in a press release. The company will offer genetic screens to patients who tested positive with the FM/a test. This will allow the identification of specific disease-related mutations and genetic markers, similar to the BRCA1/BRCA2 predictive genes for breast cancer. EpicGenetics’ associated CAMPAIGN 250 seeks to accomplish genetic screens in up to 250,000 fibromyalg
Subscribe or to access all post and page content.